Last updated: March 31, 2026
What Is BENEMID and Its Regulatory Status?
Benemid, containing probenecid, is an FDA-approved prescription drug primarily used to treat gout and to increase antibiotic serum levels. It was approved by the FDA in 1960. Its regulatory status remains unchanged with no recent alternative indications or major label updates, positioning it as a long-standing, off-patent medication.
Market Size and Demand Drivers
Gout and Hyperuricemia Prevalence
- Estimated US prevalence: 8.3 million adults (CDC, 2019).
- Global prevalence: approximately 4% of adults, expected to rise with aging populations.
- Therapeutic focus: management of gout, hyperuricemia, and certain kidney conditions.
Competition Landscape
- Primary competitors: allopurinol (Zyloprim), febuxostat (Uloric); newer agents such as pegloticase.
- Market share: allopurinol dominates with over 70% in the gout market.
- Patent status: off-patent, leading to generic dominance.
Pricing and Reimbursement Trends
- Average retail price (ARDx): $15–$25 per prescription.
- Insurance coverage: broad due to generic status, with high claim approval rates.
- Generics' presence limits price inflation, contributing to stable revenue streams.
Supply Chain and Manufacturing Factors
- Manufacturing is characterized by high-quality generic APIs produced by multiple suppliers.
- Market entry barriers are low due to established manufacturing processes.
- Supply stability is high, with no recent disruptions reported.
Market Dynamics Influencing Future Sales
Patent and Regulatory Environment
- No patent protections; reliant on generic competition.
- No recent FDA label expansions or indications.
Healthcare Trends
- Rising rates of gout linked to obesity, aging, increased comorbidities.
- Shift toward combination therapies and newer uric acid-lowering agents.
Potential Off-Label and Adjunct Uses
- Some off-label use in renal protection and drug toxicity management.
- Little evidence to suggest significant growth in these areas.
Financial Trajectory Analysis
| Aspect |
Current State |
Future Outlook |
| Revenue |
Stable, with estimated annual sales around $10–$15 million globally |
Slight decline expected due to generic competition; potential upsurge if used in adjunct indications or combination therapy |
| Patent status |
Off-patent; generic market saturation persists |
No patent protection; low revenue growth potential |
| Pricing trends |
Stable with minor fluctuations |
Likely flat or decreasing due to competition and market saturation |
| Market penetration |
Mature in key markets; slow growth |
Limited growth; potential niche repositioning |
| R&D investment |
None or minimal; primarily manufacturing and compliance |
None expected; focus on cost management |
Financial Risk Factors
- Price erosion due to generic competition.
- Regulatory pressures limiting label expansion.
- Market saturation in established indications.
Opportunities
- Repurposing for new indications remains unlikely given current data.
- Entry into emerging markets driven by rising gout prevalence could provide incremental revenues.
Summary
Benemid’s sales trajectory remains stable but slow due to generic competition and lack of new indications. The market is mature with limited growth prospects unless developments enable repositioning or new clinical evidence promotes off-label use. Cost management and supply chain stability remain critical to maintaining margins.
Key Takeaways
- Benemid has sustained its market presence over decades with stable demand for gout management.
- The generic landscape limits revenue growth, with pricing pressure at the forefront.
- No recent regulatory or patent barriers offer avenues for rapid expansion.
- Rising gout prevalence may sustain modest sales, primarily in mature markets.
- Future value creation hinges on niche repositioning or regulatory approval for new uses, which appears unlikely given current data.
FAQs
1. Is there potential for Benemid to regain patent protection?
No. As a long-established off-patent drug, patent claims are no longer active, and new patents are unlikely without significant innovation.
2. Can Benemid be used for indications beyond gout?
Current evidence does not support significant off-label market expansion. Future use depends on clinical trials demonstrating benefit in other conditions.
3. How does Benemid compare in market share to newer uric acid-lowering agents?
It has a minimal market share in comparison to newer agents like febuxostat, but its low cost and established safety profile sustain its niche role.
4. How will price trends evolve for Benemid?
Prices are expected to remain stable or decline slightly due to generic competition and payer negotiations.
5. What are the primary risks for Benemid’s future sales?
Generic price erosion, slow demand growth, and limited indication expansion.
References
[1] Centers for Disease Control and Prevention. (2019). Economic costs of gout in the United States.
[2] U.S. Food and Drug Administration. (1960). Drug approval records for probenecid.
[3] MarketResearch.com. (2022). Global gout therapeutics market report.
